VYNE Therapeutics Granted Nasdaq Extension to Regain Compliance

The latest update is out from VYNE Therapeutics ( (VYNE) ).

On September 12, 2025, VYNE Therapeutics disclosed that it had fallen out of compliance with Nasdaq’s $1.00 minimum bid price requirement after its shares traded below that threshold for 30 consecutive business days and was given until March 10, 2026, to regain compliance. After failing to meet that deadline, VYNE received an extension notice from Nasdaq on March 11, 2026, granting the company an additional 180 days, until September 7, 2026, to restore its share price, with its stock continuing to trade normally while management monitors the bid price and considers options such as a potential reverse stock split to avoid possible delisting.

The most recent analyst rating on (VYNE) stock is a Hold with a $0.60 price target. To see the full list of analyst forecasts on VYNE Therapeutics stock, see the VYNE Stock Forecast page.

Spark’s Take on VYNE Stock

According to Spark, TipRanks’ AI Analyst, VYNE is a Neutral.

The score is held down primarily by very weak financial performance (tiny revenue base, ongoing large losses, and significant cash burn) despite low leverage. Technicals add modest support with improving near-term momentum, and the merger/financing event is a notable positive for runway and strategy, but valuation remains unattractive/unclear due to negative earnings and no dividend.

To see Spark’s full report on VYNE stock, click here.

More about VYNE Therapeutics

VYNE Therapeutics Inc. is a biopharmaceutical company whose common stock trades on the Nasdaq Capital Market under the symbol VYNE. The company is subject to Nasdaq’s continued listing standards, including minimum bid price and market value requirements for its publicly held shares.

Average Trading Volume: 5,322,779

Technical Sentiment Signal: Hold

Current Market Cap: $20.05M

Learn more about VYNE stock on TipRanks’ Stock Analysis page.